ERBB2 and breast carcinoma: The phase III PHOEBE study: Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE) confirmed that pyrotinib demonstrated good clinical efficacy in patients with progressive HER-2–positive breast cancer previously treated with trastuzumab combined with paclitaxel (26).